Protagonist to opt out of Takeda profit-sharing deal, will receive $400M in cashnews2026-02-26T14:58:16+00:00February 26th, 2026|Endpoints News|
Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer news2026-02-26T14:52:14+00:00February 26th, 2026|Endpoints News|
Salma Health raises $80M for its clinics to treat brain healthnews2026-02-26T14:00:16+00:00February 26th, 2026|Endpoints News|
OrbiMed jumps to number one on the top 100 list of biotech venture investorsnews2026-02-26T12:00:39+00:00February 26th, 2026|Endpoints News|
Lilly’s GLP-1 pill beats Novo’s in diabetes trial, has more side effectsnews2026-02-26T11:30:10+00:00February 26th, 2026|Endpoints News|
Japan’s Asahi Kasei to buy German biotech Aicuris for $920Mnews2026-02-26T08:28:00+00:00February 26th, 2026|Endpoints News|
Gilead, Merck plan to debut new daily HIV pillsnews2026-02-25T21:01:54+00:00February 25th, 2026|Endpoints News|
Make way, Camzyos: Cytokinetics touts promising early launch for rival heart drugnews2026-02-25T20:17:20+00:00February 25th, 2026|Endpoints News|
Charles River sells its CDMO and European discovery businessesnews2026-02-25T16:22:03+00:00February 25th, 2026|Endpoints News|
